FDA warning letters to GLP-1 telehealth companies in 2026: what they mean if you are a patient

If you are on a compounded GLP-1, or thinking about starting one, you may have seen headlines about the FDA sending warning letters to telehealth companies. It is reasonable to wonder whether your provider is one of them, whether your prescription is still legal, and whether you should stop. This post explains what the letters actually said, what they did not say, and how to check any provider yourself.

What happened

On March 3, 2026, the FDA announced warning letters to 30 telehealth companies over their marketing of compounded GLP-1 medications. In June 2026 it posted letters to 25 more. Separately, on April 30, 2026, it proposed ending 503B bulk compounding of tirzepatide and semaglutide, a different action covered in our guide to the 2026 compounding rules.

The warning letters were about marketing claims, not about whether compounding itself is allowed. The FDA objected to two patterns in particular:

• Claims presenting a compounded product as interchangeable with an FDA-approved drug such as Zepbound, Mounjaro, Wegovy, or Ozempic
• Branding a compounded product with the telehealth company's own name without making clear which pharmacy actually compounded it
• Language implying FDA approval, including 'FDA-approved ingredients' framing that blurs the difference between an ingredient and an approved finished drug

What the letters did not say

A warning letter is not a recall, and it is not a finding that a specific patient's medication was unsafe. It tells a company that the FDA considers certain claims misleading and asks it to correct them. Patient-specific compounding by a state-licensed 503A pharmacy, under a prescription from a licensed provider who documents a clinical need, was not the subject of these letters.

So if your provider received a letter, that does not automatically mean your medication is unsafe. It does mean the company told you something about its product that the FDA considers misleading, and that is worth weighing when you decide whether to trust it with your care.

Five things to check about any GLP-1 provider

• Does it say plainly that compounded medication is not FDA-approved, and not a generic? If it calls its product the same drug as a brand, that is the exact claim the letters targeted.
• Does it tell you what kind of pharmacy prepares your medication (503A or 503B) and that the pharmacy is US-licensed?
• Is a licensed provider actually reviewing your health history, or does approval look automatic?
• Is the full price shown before you pay, including what happens after the first month and how to cancel?
• Does it separate clinical-trial results for the molecule (SURMOUNT, STEP) from its own patient outcomes? Trial data presented as a company's own results is a red flag.

How StaveMD handles this

Compounded medication prescribed through StaveMD is prepared by a US-licensed 503A compounding pharmacy for you specifically, under a prescription from a licensed provider. It is a different, non-FDA-approved finished product, not a generic and not a substitute for a brand-name drug. A provider prescribes it only when it is clinically appropriate for you. StaveMD does not compound or manufacture medication. The efficacy figures on this site come from published trials of the molecule, not StaveMD patient data. Our price is shown in full before you pay, and you can cancel any time from your account.

If you are switching from a program that changed its offering, you do not have to start from scratch. See how to switch GLP-1 providers without starting over.